Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 6
2019 8
2020 12
2021 7
2022 5
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Corrigendum: Lipid metabolism in tumor immunology and immunotherapy.
Duong LK, Corbali HI, Riad TS, Ganjoo S, Nanez S, Voss T, Barsoumian HB, Welsh J, Cortez MA. Duong LK, et al. Among authors: barsoumian hb. Front Oncol. 2024 Jan 8;13:1358498. doi: 10.3389/fonc.2023.1358498. eCollection 2023. Front Oncol. 2024. PMID: 38260855 Free PMC article.
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.
Hu Y, Paris S, Sahoo N, Bertolet G, Wang Q, Wang Q, Barsoumian HB, Da Silva J, Huang A, Doss DJ, Pollock DP, Hsu E, Selene N, Leyton CSK, Voss TA, Masrorpour F, Ganjoo S, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Hu Y, et al. Among authors: barsoumian hb. JCI Insight. 2023 Jun 22;8(12):e167749. doi: 10.1172/jci.insight.167749. JCI Insight. 2023. PMID: 37345658 Free PMC article.
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer.
He K, Barsoumian HB, Puebla-Osorio N, Hu Y, Sezen D, Wasley MD, Bertolet G, Zhang J, Leuschner C, Yang L, Kettlun Leyton CS, Fowlkes NW, Green MM, Hettrick L, Chen D, Masrorpour F, Gu M, Maazi H, Revenko AS, Cortez MA, Welsh JW. He K, et al. Among authors: barsoumian hb. Cancer Immunol Res. 2023 Apr 3;11(4):486-500. doi: 10.1158/2326-6066.CIR-22-0547. Cancer Immunol Res. 2023. PMID: 36700864 Free PMC article.
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model.
Hu Y, Paris S, Bertolet G, Barsoumian HB, Wang Q, Da Silva J, Patel NB, Nguyen N, Doss DJ, Huang A, Hsu E, Leyton CSK, Voss TA, Masrorpour F, Leuschner C, Pietz JT, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Hu Y, et al. Among authors: barsoumian hb. Front Immunol. 2022 Nov 3;13:1022011. doi: 10.3389/fimmu.2022.1022011. eCollection 2022. Front Immunol. 2022. PMID: 36405757 Free PMC article.
Pulsed radiotherapy to mitigate high tumor burden and generate immune memory.
Sezen D, Barsoumian HB, He K, Hu Y, Wang Q, Abana CO, Puebla-Osorio N, Hsu EY, Wasley M, Masrorpour F, Wang J, Cortez MA, Welsh JW. Sezen D, et al. Among authors: barsoumian hb. Front Immunol. 2022 Oct 6;13:984318. doi: 10.3389/fimmu.2022.984318. eCollection 2022. Front Immunol. 2022. PMID: 36275767 Free PMC article.
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.
Hu Y, Paris S, Bertolet G, Barsoumian HB, He K, Sezen D, Chen D, Wasley M, Silva JD, Mitchell JA, Voss TA, Masrorpour F, Leyton CK, Yang L, Leuschner C, Puebla-Osorio N, Gandhi S, Nguyen QN, Cortez MA, Welsh JW. Hu Y, et al. Among authors: barsoumian hb. J Nanobiotechnology. 2022 Sep 19;20(1):417. doi: 10.1186/s12951-022-01621-4. J Nanobiotechnology. 2022. PMID: 36123677 Free PMC article.
42 results